Read on Twitter
By popular demand 
The Top 10 clinical publications in Oncology in 2020 (In no particular order). Some important papers bundled + Additional 5 more papers representing major advances in the field @OncoAlert
1. Pembrolizumab led to significantly longer progression-free survival vs chemotherapy as first-line therapy for MSI-HâdMMR metastatic colorectal cancer Pembrolizumab in Microsatellite-InstabilityâHigh Advanced Colorectal Cancer @NEJM @agrothey https://www.nejm.org/doi/full/10.1056/NEJMoa2017699#.X-3UYdNSFSY.twitter
Pembrolizumab in Microsatellite-InstabilityâHigh Advanced Colorectal Cancer @NEJM @agrothey https://www.nejm.org/doi/full/10.1056/NEJMoa2017699#.X-3UYdNSFSY.twitter
2. Most children with neurofibromatosis type 1 and inoperable plexiform neurofibromas had durable tumor shrinkage and clinical benefit from selumetinib Selumetinib in Children with Inoperable Plexiform Neurofibromas @NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa1912735#.X-3VVi5Tncs.twitter
Selumetinib in Children with Inoperable Plexiform Neurofibromas @NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa1912735#.X-3VVi5Tncs.twitter
3. Vaccine prevents cancerQuadrivalent HPV vaccination was associated with a substantially reduced risk of invasive cervical cancer at the population level HPV Vaccination and the Risk of Invasive Cervical Cancer @NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa1917338#.X-3Vs2Ocmfc.twitter
Quadrivalent HPV vaccination was associated with a substantially reduced risk of invasive cervical cancer at the population level HPV Vaccination and the Risk of Invasive Cervical Cancer @NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa1917338#.X-3Vs2Ocmfc.twitter
4. Finally the undruggable KRAS is druggable KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors @NEJM @DavidHongMD https://www.nejm.org/doi/full/10.1056/NEJMoa1917239#.X-3WK_N46bY.twitter
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors @NEJM @DavidHongMD https://www.nejm.org/doi/full/10.1056/NEJMoa1917239#.X-3WK_N46bY.twitter
5. Selective RET inhibitor alter the landscape of RET cancers Efficacy of Selpercatinib in RET FusionâPositive & thyroid cancer ( COI: Senior/co-senior author in both papers) @NEJM https://bit.ly/3aWQOZx https://www.nejm.org/doi/full/10.1056/NEJMoa2005653#.X-3Whr4eiZw.twitter
Efficacy of Selpercatinib in RET FusionâPositive & thyroid cancer ( COI: Senior/co-senior author in both papers) @NEJM https://bit.ly/3aWQOZx https://www.nejm.org/doi/full/10.1056/NEJMoa2005653#.X-3Whr4eiZw.twitter
6. GUAvelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma @PGrivasMDPhD + OS Analysis of the PROfound Study: @myESMO @neerajaiims
@NEJM
â Link: https://nejm.org/doi/full/10.1056/NEJMoa2022485 https://bit.ly/3aWRwGb
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma @PGrivasMDPhD + OS Analysis of the PROfound Study: @myESMO @neerajaiims @NEJM
â Link: https://nejm.org/doi/full/10.1056/NEJMoa2022485 https://bit.ly/3aWRwGb
7. Cholangiocarcinoma. Pemigatinib for FGFR & Dabrafenib+ Trametinib BRAFV600 + cholangiocarcinoma. Two @TheLancetOncol publications. ( COI: PI of BRAF trial) https://bit.ly/3hyCFCM https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30321-1/fulltext#.X-3a7tjTGXI.twitter
8. From a tweet to @TheLancet in 10 weeks. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study @hemoncwarner @DrChoueiri @ADesaiMD @PGrivasMDPhD @corrie_painter https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31187-9/fulltext#.X-3bl4SZajM.twitter
9. Anti-biotic therapy reduces risk of cancer Family History of Gastric Cancer and Helicobacter pylori Treatment @NEJM @ShaalanBeg @cancerassassin1 @MiteshBorad https://www.nejm.org/doi/full/10.1056/NEJMoa1909666#.X-3cbcpKm7M.twitter
Family History of Gastric Cancer and Helicobacter pylori Treatment @NEJM @ShaalanBeg @cancerassassin1 @MiteshBorad https://www.nejm.org/doi/full/10.1056/NEJMoa1909666#.X-3cbcpKm7M.twitter
10. The ADAURA study. Maybe controversial but still a major advance in EGFR NSCLC & opens door for many other adjuvant studies Osimertinib in Resected EGFR-Mutated NonâSmall-Cell Lung Cancer @NEJM @JackWestMD @n8pennell @StephenVLiu https://www.nejm.org/doi/full/10.1056/NEJMoa2027071#.X-3cowdzOd8.twitter
Osimertinib in Resected EGFR-Mutated NonâSmall-Cell Lung Cancer @NEJM @JackWestMD @n8pennell @StephenVLiu https://www.nejm.org/doi/full/10.1056/NEJMoa2027071#.X-3cowdzOd8.twitter
11. EZH2 inhibition for epithelioid sarcoma and follicular lymphoma 2 @TheLancetOncol papers + editorial https://bit.ly/3aWWjr9 https://bit.ly/38MF6xT https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30441-1/fulltext#.X-3grJ1RQHc.twitter
12. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30445-9/fulltext#.X-3g8hiY4YE.twitter
13. Capmatinib & Teoptinib in MET Exon 14âMutated or MET-Amplified NonâSmall-Cell Lung Cancer @NEJM @StephenVLiu https://www.nejm.org/doi/full/10.1056/NEJMoa2004407#.X-3hTfdsTr4.twitter https://www.nejm.org/doi/full/10.1056/NEJMoa2002787#.X-3hHQEp0SE.twitter
14. The Effect of Advances in Lung-Cancer Treatment on Population Mortality @NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa1916623#.X-3hsfX406g.twitter
15. Pfizer + Moderna #COVID19 vaccine studies. Not oncology but will prevent COVID19 infection in patients with cancer in the future + Protect #healthcareworkers + researchers in Cancer @oncoalert https://www.nejm.org/doi/full/10.1056/NEJMoa2034577#.X-3iKsNQf3A.twitter https://www.nejm.org/doi/full/10.1056/NEJMoa2035389#.X-3iakXbYgw.twitter
